Literature DB >> 12464111

Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity.

H I Mosberg1, C B Fowler.   

Abstract

Opioid receptor binding conformations for two structurally related, conformationally constrained tetrapeptides, JOM-6 ( micro receptor selective) and JOM-13 (delta receptor selective), were deduced using conformational analysis of these ligands and analogs with additional conformational restrictions. Docking of these ligands in their binding conformations to opioid receptor structural models, based upon the published rhodopsin X-ray structure, implicates specific structural features of the micro and delta receptor ligand binding sites as forming the basis for the micro selectivity of JOM-6 and the delta selectivity of JOM-13. In particular, the presence of E229 in the micro receptor (in place of the corresponding D210 of the delta receptor) causes an adverse electrostatic interaction with C-terminal carboxylate-containing ligands, resulting in the observed preference of ligands with an uncharged C-terminus for the micro receptor. In addition, the requirement that the Phe3 side chain of JOM-13 assume a gauche orientation for optimal delta binding, whereas the Phe3 side chain of JOM-6 must be in a trans orientation for high-affinity micro binding can be largely attributed to the steric effect of replacement of L300 of the delta receptor by W318 of the micro receptor. Testing this hypothesis by examining the binding of JOM-6 and several of its key analogs with specific micro receptor mutants is described. Our initial results are consistent with the proposed ligand-receptor interaction models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464111     DOI: 10.1034/j.1399-3011.2002.21061.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  13 in total

Review 1.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  Ubiquitination regulates proteolytic processing of G protein-coupled receptors after their sorting to lysosomes.

Authors:  James N Hislop; Anastasia G Henry; Adriano Marchese; Mark von Zastrow
Journal:  J Biol Chem       Date:  2009-05-11       Impact factor: 5.157

3.  Synthesis, pharmacological evaluation and conformational investigation of endomorphin-2 hybrid analogues.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Engin Bojnik; Anna Borsodi; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  Mol Divers       Date:  2012-11-04       Impact factor: 2.943

4.  N-methylated cyclic enkephalin analogues retain high opioid receptor binding affinity.

Authors:  Grazyna Weltrowska; Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-12-17       Impact factor: 2.817

5.  Structural and biological exploration of phe(3)-phe(4)-modified endomorphin-2 peptidomimetics.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Thomas F Murray; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

6.  Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.

Authors:  Karina Martinez-Mayorga; Kendall G Byler; Austin B Yongye; Marc A Giulianotti; Colette T Dooley; Richard A Houghten
Journal:  Eur J Med Chem       Date:  2013-05-30       Impact factor: 6.514

7.  Cyclic enkephalins with a diversely substituted guanidine bridge or a thiourea bridge: synthesis, biological and structural evaluations.

Authors:  Engin Bojnik; Baptiste Legrand; Youness Touati-Jallabe; Elodie Mauchauffée; Nga N Chung; Peter W Schiller; Sandor Benyhe; Marie-Christine Averlant-Petit; Jean Martinez; Jean-Franćois Hernandez
Journal:  J Med Chem       Date:  2013-07-12       Impact factor: 7.446

Review 8.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

9.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.